159 related articles for article (PubMed ID: 22856663)
1. Targeting Bcl-2 in CLL.
Rogalinska M; Kilianska ZM
Curr Med Chem; 2012; 19(30):5109-15. PubMed ID: 22856663
[TBL] [Abstract][Full Text] [Related]
2. Progress in BCL2 inhibition for patients with chronic lymphocytic leukemia.
Tam CS; Seymour JF; Roberts AW
Semin Oncol; 2016 Apr; 43(2):274-9. PubMed ID: 27040706
[TBL] [Abstract][Full Text] [Related]
3. Design of novel BH3 mimetics for the treatment of chronic lymphocytic leukemia.
Billard C
Leukemia; 2012 Sep; 26(9):2032-8. PubMed ID: 22453662
[TBL] [Abstract][Full Text] [Related]
4. Targeting the apoptotic pathway with BCL-2 inhibitors sensitizes primary chronic lymphocytic leukemia cells to vesicular stomatitis virus-induced oncolysis.
Tumilasci VF; Olière S; Nguyên TL; Shamy A; Bell J; Hiscott J
J Virol; 2008 Sep; 82(17):8487-99. PubMed ID: 18579592
[TBL] [Abstract][Full Text] [Related]
5. Development of Noxa-like BH3 mimetics for apoptosis-based therapeutic strategy in chronic lymphocytic leukemia.
Billard C
Mol Cancer Res; 2012 Jun; 10(6):673-6. PubMed ID: 22466256
[TBL] [Abstract][Full Text] [Related]
6. BCL-2 Inhibitors, Present and Future.
Ryan CE; Davids MS
Cancer J; 2019; 25(6):401-409. PubMed ID: 31764121
[TBL] [Abstract][Full Text] [Related]
7. Critical molecular pathways in CLL therapy.
Ferrer G; Montserrat E
Mol Med; 2018 Mar; 24(1):9. PubMed ID: 30134797
[TBL] [Abstract][Full Text] [Related]
8. The first MCL-1-selective BH3 mimetics have therapeutic potential for chronic lymphocytic leukemia.
Besbes S; Pocard M; Mirshahi M; Billard C
Crit Rev Oncol Hematol; 2016 Apr; 100():32-6. PubMed ID: 26899021
[TBL] [Abstract][Full Text] [Related]
9. Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibition.
Davids MS; Letai A; Brown JR
Leuk Lymphoma; 2013 Aug; 54(8):1823-5. PubMed ID: 23614795
[TBL] [Abstract][Full Text] [Related]
10. Bcl-2 antagonists: a proof of concept for CLL therapy.
Balakrishnan K; Gandhi V
Invest New Drugs; 2013 Oct; 31(5):1384-94. PubMed ID: 23907405
[TBL] [Abstract][Full Text] [Related]
11. CD154 induces a switch in pro-survival Bcl-2 family members in chronic lymphocytic leukaemia.
Willimott S; Baou M; Naresh K; Wagner SD
Br J Haematol; 2007 Sep; 138(6):721-32. PubMed ID: 17760804
[TBL] [Abstract][Full Text] [Related]
12. A review of the role of Puma, Noxa and Bim in the tumorigenesis, therapy and drug resistance of chronic lymphocytic leukemia.
Zhang LN; Li JY; Xu W
Cancer Gene Ther; 2013 Jan; 20(1):1-7. PubMed ID: 23175245
[TBL] [Abstract][Full Text] [Related]
13. BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells.
Pérez-Galán P; Roué G; López-Guerra M; Nguyen M; Villamor N; Montserrat E; Shore GC; Campo E; Colomer D
Leukemia; 2008 Sep; 22(9):1712-20. PubMed ID: 18596739
[TBL] [Abstract][Full Text] [Related]
14. The role of Bcl-2 family proteins in chronic lymphocytic leukaemia.
Buggins AG; Pepper CJ
Leuk Res; 2010 Jul; 34(7):837-42. PubMed ID: 20359747
[TBL] [Abstract][Full Text] [Related]
15. Bcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells.
Campàs C; Cosialls AM; Barragán M; Iglesias-Serret D; Santidrián AF; Coll-Mulet L; de Frias M; Domingo A; Pons G; Gil J
Exp Hematol; 2006 Dec; 34(12):1663-9. PubMed ID: 17157163
[TBL] [Abstract][Full Text] [Related]
16. Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.
Del Poeta G; Postorino M; Pupo L; Del Principe MI; Dal Bo M; Bittolo T; Buccisano F; Mariotti B; Iannella E; Maurillo L; Venditti A; Gattei V; de Fabritiis P; Cantonetti M; Amadori S
Drugs Today (Barc); 2016 Apr; 52(4):249-60. PubMed ID: 27252989
[TBL] [Abstract][Full Text] [Related]
17. Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia.
Roberts AW; Stilgenbauer S; Seymour JF; Huang DCS
Clin Cancer Res; 2017 Aug; 23(16):4527-4533. PubMed ID: 28100580
[TBL] [Abstract][Full Text] [Related]
18. BCL-2 as a therapeutic target in chronic lymphocytic leukemia.
Daniel C; Mato AR
Clin Adv Hematol Oncol; 2017 Mar; 15(3):210-218. PubMed ID: 28398276
[TBL] [Abstract][Full Text] [Related]
19. P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia.
Johnston JB; Daeninck P; Verburg L; Lee K; Williams G; Israels LG; Mowat MR; Begleiter A
Leuk Lymphoma; 1997 Aug; 26(5-6):435-49. PubMed ID: 9389352
[TBL] [Abstract][Full Text] [Related]
20. Therapeutics targeting Bcl-2 in hematological malignancies.
Ruefli-Brasse A; Reed JC
Biochem J; 2017 Oct; 474(21):3643-3657. PubMed ID: 29061914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
